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Abstract
Solid organ fabrication is an ultimate goal of Regenerative Medicine. Since the introduction of Tissue Engineering in
1993, functional biomaterials, stem cells, tunable microenvironments, and high-resolution imaging technologies
have significantly advanced efforts to regenerate in vitro culture or tissue platforms. Relatively simple flat or tubular
organs are already in (pre)clinical trials and a few commercial products are in market. The road to more complex,
high demand, solid organs including heart, kidney and lung will require substantive technical advancement. Here,
we consider two emerging technologies for solid organ fabrication. One is decellularization of cadaveric organs
followed by repopulation with terminally differentiated or progenitor cells. The other is 3D bioprinting to deposit
cell-laden bio-inks to attain complex tissue architecture. We reviewed the development and evolution of the two
technologies and evaluated relative strengths needed to produce solid organs, with special emphasis on the heart
and other tissues of the cardiovascular system.
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Background
Tissue Engineering, as introduced in 1993 [1], is the cre-
ation of complex tissues and organs from simpler engi-
neered pieces. Over the past few decades, biomaterials,
stem cell technology and advanced imaging modalities
have been developed to generate tissue components.
Biomaterials are not only a delivery vehicle or passive
scaffold for cells, but dynamically modulated microenvi-
ronments in vivo and in vitro. Synthetic biomaterials
possess well-defined physicochemical properties and
synthetic-natural hybrid biomaterials often present tun-
able biological functionalities. Stem cell biology with re-
programming and gene-editing provides more options
for cell sources in tissue engineered constructs. Ad-
vanced imaging techniques enable acquisition of more
detailed spatiotemporal information, which can serve as
a blue print for tissue regeneration [2, 3].
Earlier approaches in Tissue Engineering focused on 2D
organs such as skin and hollow tubular (e.g. blood vessels)
or non-tubular hollow organs (e.g. bladder). Solid organs
such as kidney, liver or heart are the most complex in
achieving vascularization and innervation [4]. Thus solid
organs are more than a collection of 2D tissue compo-
nents and need to be created by exploiting all-in-one ap-
proaches from the beginning. Generating simple 2D or
hollow organs is feasible with cell and supporting scaffold
of only one type by molding them into a pre-designed
cast. However, molding-based fabrication is challenging to
accommodate multiple cell types and the extracellular
matrix (ECM) in 3D space to achieve tissue-mimicking
patterns and associated spatial resolution. Fortunately two
technologies have recently emerged that are likely to facili-
tate solid organ fabrication ex vivo, namely decellularized
tissue scaffolds and 3D bioprinting. These fabrication
technologies are quite distinct in their execution (Fig. 1),
and therefore harbor distinct attributes and limitations. In
this review, we will describe decellularization and 3D bio-
printing for soft tissue regeneration in detail, and briefly
summarize the pros and cons of each especially in the
context of the cardiovascular system. We also comment
on the merging of these technologies via 3D printing with
decellularized ECM bio-ink and discuss biomimetic 4D
printing. Readers are referred to other reviews for specific,
emerging technical advances that enable 3D bioprinting
(Murphy and Atala [4], O’Brien et al. [5], Studart [6],
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Jungst et al. [7], Jose et al. [8], Guvendiren et al. [9] and
Gudapati et al. [10]).
Organogenesis via decellularization and recellularization
A number of approaches have been attempted to remove
cells and preserve intact ECM via physical, chemical and
enzymatic treatments [11]. Decellularized scaffolds provide
architecture and mechanical integrity of the remaining
ECM, while avoiding adverse biological and immunological
responses from cellular and nuclear materials. One of the
earliest approaches was to harvest the ECM of the small in-
testinal submucosa (SIS) by removing the superficial layers
of the mucosa and the external muscular layers [12]. Al-
though this was suitable for 3D in vitro cell cultures,
80 μm-thick ECMs may not have mechanical properties to
resist shear from cardiac pumping and circulation. Expand-
ing this idea to organ scale, the first decellularized heart
was described by Ott et al. [13] in 2008. This pioneering ap-
proach reported the decellularization of 12 week-old whole
rat heart while preserving the underlying ECM and intact
geometry and producing acellular and perfusable vascula-
ture (Fig. 2a). The decellularized rat heart was repopulated
with rat aortic endothelial and neonatal cardiac cells and
was matured further with physiological preload, afterload
and intraventricular pressure as well as electrical stimula-
tion at 5–20 V in a bioreactor up to 28 days. This recellu-
larized heart developed macroscopic contraction and the
measured pump function was equivalent to about 2 % of
adult or 25 % of 16-week fetal heart function. This inaug-
ural study initiated regenerative engineering approaches in
different types of solid organs including lung, kidney and
pancreas [14]. Since then, decellularization procedures have
been further optimized and critically evaluated [15].
From an organogenesis perspective, decellularized tis-
sues maintain the ECM framework, but lack the funda-
mental and biological unit of organs. Although the first
human embryonic stem cells (ESC) were derived in 1998
[16], the idea of employing stem or progenitor cells be-
came more attractive for tissue regeneration after the
introduction of induced pluripotent stem cells (iPSCs)
[17, 18]. This breakthrough stem cell technology might
enable production of a personalized heart. Followed by
decellularization, repopulating the decellularized heart
with either pluripotent stem cells or lineage-restricted
progenitor cells [19] and maturing those cells within the
intact ECMs in situ could promote the generation of
Fig. 1 Two representative regenerative medicine technologies for cardiac organogenesis. a Decellularization starts with physical, chemical, and
enzymatic treatment of cadaveric heart to remove cells while keeping the extracellular matrix of the heart. Utilizing a perfusion bioreactor, the
decellularized heart is repopulated with either progenitor cells or terminally differentiated cardiac cell types. The end goal of this strategy is to
regenerate functional heart with complete vascularization. b Functional biomaterials (ECM proteins, ECM-analogues or synthetic materials) and/or
cells (stem, progenitor or fully differentiated) serve as a bio-ink for 3D bioprinting. This controlled manufacturing technology aims to produce
spatially-defined tissues or organs at multiple length scales
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functional heart tissue. Lu et al. [20] decellularized
mouse cadaveric whole heart (Fig. 2b) and repopulated
with human iPS-derived multipotent cardiovascular pro-
genitors (MCPs), which were differentiated in situ into
cardiomyocytes, smooth muscle cells and endothelial
cells. After 20 days of perfusion, the repopulated heart ex-
hibited myocardium and vessel-like structures, contracted
spontaneously at a rate of 40–50 beats per min and
responded to isoproterenol treatment. This study also
found that cardiac ECM prompted significantly more car-
diomyocyte proliferation, differentiation and myofilament
formation from the repopulated MCPs than in a 3D
microenvironment of embryoid body. More recently,
decellularization and repopulation with iPSCs was up-
scaled to human cadaveric heart. Guyette et al. [21] pre-
pared decellularized human cadaveric whole heart from 73
donors via perfusion decellularization (Fig. 2c). Toward
better translational outcome, this group employed cardio-
myocytes from a non-transgenic (RNA-induced) PSCs [22]
by modulating the Wnt/β-catenin signaling with inhibitors
of GSK3β and Wnt [23]. The whole heart recellularization
was performed using a custom bioreactor capable of pro-
viding coronary perfusion and left ventricular wall mech-
anical stimulation that was achieved by oscillating the
pressure inside a balloon placed inside the left ventricle.
Heart is not the only candidate organ for decellularization
and repopulation with progenitors or terminally differenti-
ated cells. These approaches were also applied to liver
[24], kidney [25] and other cardiovascular tissues including
valves and vessels [26] (authors refer to a recent review by
Song and Ott [14] for further review of decellularizaton of
others organs).
Preserving vasculature and mechanical integrity of the
tissue with decellularization allows repopulation of the
decellularized organs with cells. For clinical application,
techniques to achieve complete endothelialization with
recellularization will be critical for the maintenance of
blood flow and the prevention of blood coagulation given
the thrombogenicity of certain ECM proteins of the decel-
lularized scaffold [27].
In summary, decellularization of whole organ has been
achieved with intact ECM architecture and perfusable
vasculature. Preserving vasculature and mechanical integ-
rity of the tissue with decellularization allows repopulation
of the decellularized organs with cells. Repopulation with
iPSCs have been achieved up to human scale for certain
organs. However, the number of different types of cells for
repopulation of decellularized organs is limited. In particu-
lar, the spatial acuity or precise positioning of cells is chal-
lenging to achieve as repopulation is currently dependent
on perfusion. Recently emerged 3D bioprinting technique
has the potential to fulfill some of these limitations and
complement the advantages of decellularization-based re-
generative engineering.
3D bioprinting for directed morphogenesis and
organogenesis
3D printing has been a disruptive innovation in many
areas of industry, research, medicine and education. 2D
Fig. 2 Decellularization of mammalian hearts. a Decellularization of
rat heart with 1 % SDS, 1 % Triton X-100, and antibiotic-containing
PBS. Macroscopic view of Evan’s blue dye perfusion showing intact
coronary vasculature, with permission from Nature Publishing Group
[13]. b Decellularization of mouse heart with trypsin, 1 % SDS, 3 %
Triton X-100, and 0.1 % peracetic acid, with permission from Nature
Publishing Group [20]. The intact coronary vasculature visualized
with Trypan blue solution. c Cadaveric human heart before and after
perfusion decellularization, with permission from Elsevier [14]
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printing technology of materials has advanced to an
additive process in which successive layers are formed
into a 3D shape. Soon after 3D printing, termed stereo-
lithography, was first introduced in 1986 by Charles W.
Hull, it began to replace many manufacturing and molding
processes. Since medical devices or prosthetics need to be
produced with customized detail in clinics, 3D printing is
an ideal candidate to augment personalized medicine ap-
plications. Recently, combining high-resolution imaging,
computer-aided design and resorbable biomaterials, 3D
printing showcased an airway splint to treat an infant with
tracheobronchomalacia [28]. Later, further advancements
were made to include multiple types of precisely printable
biological ink (bio-ink), sacrificial biomaterials, and living
cells to fabricate bone, cartilage and skeletal muscle [29].
In this section, we will discuss the advancement of 3D
printing via biomaterials and living cells with an emphasis
on cardiovascular tissues, followed by hybrid approaches
such as 3D bioprinting with decellularized ECM for com-
plex, soft tissues.
Transition from 2D patterning to 3D bioprinting
3D bioprinting began as 2D patterning with biomaterials
with cells or multilayered 3D cell-laden hydrogels struc-
tures (for example, smooth muscle cells (SMCs) encap-
sulated in collagen type I with 16.2 μm thick layers [30].
One of the earliest attempts was to employ a Hewlett-
Packard Desktop printer (HP 550C) and a modified HP
51626a ink cartridge to print Chinese Hamster Ovary
(CHO) cells [31]. These cell suspensions (bio-inks) were
printed as a circular pattern on two different types of
hydrogel-based substrates (bio-paper) that were prepared
from either soy agar or collagen type I. Only around 8 %
of CHO cells were lysed during printing and maintained
viability up to 25 days. As biomaterials serve as instructive
cues for directing morphogenesis [32] and as protective
matrices, bio-inks (cells and biomaterials) incapable of
maintaining cell health would be detrimental to printed
tissue or organs. One intriguing bio-ink approach incorpo-
rated tissue spheroids (homo and heterocellular cell aggre-
gates) as building blocks, which were assembled into
vascularized thick tissue constructs [33]. As one example,
single- and double-layered small diameter vascular tubes
ranging from outer diameter 0.9 to 2.5 mm were generated
via layer-by-layer bioprinting and self-assembled multicel-
lular (CHOs, SMCs and fibroblasts) spheroids with agar-
ose cylinders as molding templates [34].
Complex 3D bioprinting of multiple cell types with multiple
biomaterials
From aforementioned studies, 3D bioprinting technolo-
gies further evolved to provide more complex tissue
structures by incorporating multiple biomaterials (bio-
inks) to confer appropriate biochemical and mechanical
properties to engineered organs. Since single material, sin-
gle cell type, single stage processing and simple patterns
cannot mimic the complex nature of tissues or organs, re-
cent approaches have included multiple biomaterials with
orthogonal chemistry and multiple differentiated cells or
stem cells for in situ differentiation. Also, high-resolution
image-guided patterns are now routinely printed with rea-
sonable fidelity at several micro- and sub-micrometer scales
for certain printing approaches [35].
Adapting the aforementioned inkjet printing technol-
ogy, amniotic fluid derived stem cells (AFSCs), SMCs
and endothelial cells (ECs) were printed onto a multi-cell
pie configuration in an alginate and collagen composite in
an attempt to mimic bone structure [36]. The printed com-
posite exhibited similar potassium (K) current-voltage rela-
tionships at 7 day in vitro and 4 week in vivo, indicating
the basic membrane electrical properties of SMCs were
maintained after 3D bioprinting. After 7 days in culture
and implantation, ECs in the printed composites showed
no significant difference of bradykinin-induced intracellular
Ca2+ concentration ([Ca2+]i), indicative of maintaining nor-
mal vasodilation properties. After 7 days of osteogenic in-
duction and 18-week implantation, the printed composite
expressed osteocalcin and formed bony structures with sig-
nificantly higher compressive modulus. Gaetani et al. [37]
attempted to deliver progenitor cells in a 3D-printed gel-
atin/hyaluronic acid (HA) patch to recover cardiac function
in a mouse model of myocardial infarction (MI). Sca1+ car-
diac progenitor cells (CPCs) were printed with the gelatin/
HA composite to form a woodpile array 3D structure. Over
4 weeks in cardiomyogenic differentiation, the printed
CPCs were differentiated to phenotypes expressing
troponin I, cardiac actin, and connexin43. After 4 weeks
of application to the MI area of the myocardium, the
wall thickness was increased and the infarct fibrosis
was decreased.
Complex tissue patterning via imaging technologies
As multiple cell types and multi-component bio-inks
were explored for 3D bioprinting, image-guided pattern-
ing became feasible with high-resolution imaging tech-
nologies. With inkjet printing technologies, the complex
blueprint of tissues has yet to be reproduced at single
micrometer-scale resolution. Thus, complex tissue or
vasculature patterns are challenging to transfer with high
fidelity. Two-photon laser scanning lithography (TP-
LSL) has been used to generate simple patterns with fea-
tures as small as 1 μm in the lateral direction and 5 μm
in the axial direction [35, 38]. TP-LSL was further devel-
oped to pattern vasculature of the cerebral cortex from
confocal imaging [39]. TP-LSL patterning was able to
mimic the neural and vascular components of the sube-
pendymal zone neural stem cell niche and neural pro-
genitor cells were induced to express platelet/endothelial
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cell adhesion marker-1 (PECAM-1). More complex pat-
terns of the microvasculature of the cerebral cortex were
patterned with human umbilical vein endothelial cells
(HUVECs) and mesenchymal progenitor cells (10 T1/2),
forming tubular networks in 24 h of culture. Liver func-
tions are tightly linked to the 3D microenvironments of
hepatocytes with supporting endothelial and mesenchy-
mal cells in a hexagonal lobule unit. Ma et al. [40] fabri-
cated liver lobule and vascular structures with two-step
digital light processing (DLP)-based 3D printing technol-
ogy utilizing photocrosslinkable gelatin and HA to en-
capsulate hiPSC-derived hepatic cells and supporting
cells (HUVECs and adipose-derived stem cells (ADSC)).
The 3D triculture model showed greater hepatocyte
spheroid formation by reorganizing them in the desig-
nated patterns and significantly higher expression of key
enzymes (cytochrome P450) in liver drug metabolism,
compared to 3D single hiPSC-derived progenitor cell
models.
Native tissue is a perfect bioinspired template to recre-
ate 3D printed tissue structures. Mimicking develop-
mental microenvironments can provide better signals for
which stem or progenitor cells are originated and differ-
entiated. Imaging based approaches can extract such
spatial information [2]. Hanson et al. [3] acquired bioin-
spired templates from collagen architectures of develop-
ing heart using second harmonic generation (SHG) and
spatial distribution of fibronectin, collagen type IV and
elastin from embryonic day 12.5 (E12.5) to postnatal day
2 (P2) using a series of histologic sections stained for
ECM proteins via immunofluorescence (Fig. 3a). 3D
structures were printed based on such templates using
multi-photon excitation (MPE)-based fabrication. The
primary advantage of MPE-based 3D printing is sub-
micrometer resolution to accommodate subtle and non-
uniform ECM fibrillar structures with approximately
95 % fidelity as evidenced by scanning electron micros-
copy (SEM) [35]. Limiting MPE-based 3D printing is the
inability to utilize bio-inks containing cells, though it is
possible future iterations of this technology could ac-
commodate such a feature [41].
3D printing at the organ scale; important considerations
Once complex tissue structures are obtained, maintain-
ing long-term cell survival and functionality is a key fea-
ture for regenerative medicine applications. For most
tissues, this requires vascularization. Recently, Miller et
al. [42] reported a 3D printed carbohydrate glass lattice
to feed engineered organs, where the lattice structure is
removed before introducing a homogenous cell-laden
matrix. Primary rat hepatocytes showed significantly im-
proved albumin secretion and urea synthesis in 3D
printed vasculatures compared to a 3D slab lacking
channels. To determine whether this 3D carbohydrate
glass lattice can overcome the challenge of rapid oxygen
and nutrient delivery to engineered vascularized tissue
implanted in vivo, the 3D printed microvessel network
was directly connected to rat femoral arteries [43]. The
blood flow was similar to the positive control as evi-
denced by laser Doppler imaging at 1 and 3 h post-
implantation. One limitation of the carbohydrate glass
lattice approach is the need to print at elevated
temperature (above 100 °C), which inhibits inclusion of
cells in bio-inks. Kolesky et al. [44] developed an alterna-
tive approach to print 1D, 2D and 3D vasculatures with
bio-inks including dermal fibroblasts/HUVECs and gel-
atin methacrylate at ambient temperature. To fabricate
embedded vasculature, the cell-laden bio-ink contained
fugitive ink composed of Pluronic F127 that can be eas-
ily printed and removed under mild conditions. This
group recently reported a route for printing thicker vas-
cularized tissues (>1 cm in thickness and 10 cm3 in vol-
ume) within a customized silicone-based perfusable chip
for over 6 weeks [45]. The complex microenvironments
were created first by printing hMSC-laden ink into a 3D
lattice geometry along with intervening in- and out-of-
plane features composed of fugitive ink, which trans-
formed into a vascular network lined with HUVECs.
After printing, the remaining interstitial space was filled
with human neonatal dermal fibroblast (HNDF)-laden
gelatin-fibrin mix, where hMSCs and HNDFs migrated
toward the vascular channels.
Complex patterns and heterogeneous cell-laden struc-
tures have further evolved to organ level fabrication. One
example, termed freeform reversible embedding of sus-
pended hydrogels (FRESH) [46] demonstrated the ability
to print complex anatomical architecture (Fig. 3b). After
depositing a hydrogel precursor ink within a thermorever-
sible support bath (gelatin microparticles), in situ gelling
was initiated at ambient conditions and then, the printed
structure was heated to 37 °C to melt away the gelatin sup-
port bath. Using the FRESH printing approach, CT (com-
puted tomography) or MRI (magnetic resonance imaging)
data from bifurcated coronary arteries, femur, trabeculated
embryonic heart, or human brain can be printed up to sev-
eral millimeter scales at a resolution of around 200 μm
from computer aided design (CAD) files. Another example
demonstrated that human-scale tissue constructs could be
printed using cell-laden hydrogels to fabricate bone, cartil-
age, and muscle tissues. Kang et al. [29] acquired med-
ical imaging (CT or MRI) data and processed them in
CAD software, translated to a series of command list
for 3D printer XYZ stage movement and actuating pneu-
matic pressure and printed composite hydrogels for cell
delivery including gelatin, fibrinogen, HA and glycerol
mixed into high glucose DMEM (Dulbecco’s Modified
Eagle Medium). This integrated tissue-organ printer
(ITOP) was capable of printing at a resolution of 2 μm for
Jung et al. Biomaterials Research  (2016) 20:27 Page 5 of 11
biomaterials and around 50 μm for cells. Simultaneous
printing of an outer sacrificial hydrogel that is dissolved
later imparted mechanical strength to maintain the shape
of the printed structures while creating an array of micro-
channels permissive to nutrient and oxygen diffusion into
the printed structures. By modulating the patterns of the
load-bearing poly(ε-caprolactone, PCL) with respect to
other cell-laden bio-inks or sacrificial materials (Pluronic
F-127), the mechanical properties could be tuned for dif-
ferent tissue or organ applications. For example, the au-
thors printed stiffer structures that were for mandible
bone or ear-shaped cartilage while more porous structures
were employed to print skeletal muscle constructs.
3D printing with decellularized ECM bio-ink
To fabricate solid organs, we have discussed approaches
to utilize the ECM from decellularized organs (primarily
heart) or to print cell-laden bio-inks consisting of multiple
ECM proteins and cells (Fig. 1). In addition to these ex-
tracted and purified ECM proteins, decellularized ECM
(dECM) has been processed and self-assembled as an in-
jectable biomaterial for tissue recovery [47, 48] or cell
Fig. 3 3D bioprinting of complex solid organs and biomimetic 4D printing. a A single section showing collagen type IV immunofluorescence
staining in a postnatal day 2 ventricle. The stack of images was used to create a 3D reconstruction of the collagen type IV labeled serial sections
and a solid stereolithography rendering was generated from the stack of 20 serial sections. Multi-photon excitation-based fabrication was then
used to create a 3D construction, V indicates blood vessel [3]. Confocal images of fibronectin immunofluorescence staining from mouse ventricle
and the fabricated structure created through modulated raster scanning, with permission from the Optical Society [35]. A blood vessel was indicated by
the arrow. b An explanted embryonic chicken heart was stained for fibronectin (green), nuclei (blue), and F-actin (red). A cross-section of the fluorescence
alginate (green) scaffold was printed from the 3D CAD model of the embryonic heart with the internal trabeculation utilizing the FRESH technology,
with permission from the American Association of the Advancement of Science [46]. c 4D printing pathways [69]; mathematical surface was generated
from natural inspiration and the path was printed with hydrogel composite ink of cellulose fibrils. Anisotropic swelling of the composite ink transformed
the printed 2D paths into a 3D structure
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culture templates to maintain more mature phenotypes in
vitro [49]. Pati et al. [50] harvested multiple types of tis-
sues to prepare dECM bio-ink and printed cell-laden
dECM bio-inks with a PCL framework, where this print-
ing technology was capable of printing feature sizes either
at 100 or 200 μm. This multi-head tissue/organ building
system (termed MtoBS) extruded cell-laden dECM bio-
ink at 15 °C, while the printed structures were solidified at
37 °C. To accommodate different stiffness of printed tis-
sues, MtoBS can print 100 μm without the PCL frame-
work for less stiff tissues or 200 μm with the PCL
framework for stiffer tissues or organs. Encapsulated hu-
man inferior turbinate tissue-derived mesenchymal stro-
mal cells in the 3D printed tissues were able to upregulate
the gene expression of cells from which the parental
dECM was derived. For example, the heart tissue-derived
ECM significantly promoted the expression of cardiogenic
proteins Myh6 and Actn1, in comparison to 3D collagen
gels. The same group also reported that 3D printed dome-
shaped adipose tissue (from decellularized lipoaspirate)
were able to differentiate human adipose-derived stem
cells into PPAR-γ (peroxisome proliferator-activated
receptor-γ) expressing phenotypes in vitro and in vivo
[51]. Further, they were able to tailor material properties
of dECM bio-ink via vitamin B2-induced UVA crosslink-
ing and thermal gelation to enable printing of CPCs in a
construct with biomechanical properties of native cardiac
tissue [52].
In sum, 3D bioprinting has emerged from thermal ink-
jet printing of single components to the utilization of
multiple biomaterials and multiple progenitor and/or
stromal cell types with in situ differentiation. Multi-
photon imaging-based methods augmented the evolu-
tion of 3D bio printing by utilized intact, native ECM
and achieving sub-micrometer resolution. Incorporating
vasculature has been a design criterion from the begin-
ning to maintain the long-term patency of 3D printed
structures both in vivo and in vitro and approaches to
meet this criterion are underway. Most recent 3D bio-
printing technologies demonstrated feasibility of creating
complex anatomical structures based on templates ac-
quired from CT or MR imaging. Finally, digested, dECM
has also been used as a component of cell-laden bio-ink
to stimulate differentiation of printed stem cells.
Comparison of decellularization to 3D bioprinting
Decellularization of tissue and 3D bioprinting of tissue-
like constructs have potential to achieve solid organs ex
vivo, but each is executed in a completely different fash-
ion. Here, we compare these two technologies such that
they might be most appropriately applied to a given
tissue-type or regenerative medicine application (Table 1).
An important attribute for most engineered tissues is
the ability to localize cells and matrix with spatial acuity
in that augmented functionality is not compromised in
the long run. The overall shape and size of a solid organ
with decellularization is relatively well conserved in this
top down approach (Figs. 1a and 2). Decellularization
maintains the natural scaffold with corresponding com-
plex architecture including blood vessels necessary for
perfusion-based repopulation. Overall, the structure of
the native tissue is more likely to be well-mimicked with
Table 1 Comparison of features of decellularized tissue vs. 3D bioprinting for solid organ fabrication
Feature Decellularization 3D Bioprinting
Architecture Fidelity Retains complex, intact ECM architecture. Retains
vascular tree supportive of recellularization.
Attains moderately complex geometries with precision.
Simple structures with vasculature have been printed.
Cell Positioning Precise cell positioning is not possible. Recellularization
is perfusion- based and therefore stochastic.
Specific localization of cells at multiple length scales is possible.
Biochemical Signaling Innate ECM- based biochemical signaling. Biochemical cues are provided through incorporation of ECM,
growth factors or other signaling molecules into the bio-ink.
Mechanical Integrity Decellularized organs are mechanically weak with
limited ability to resist shear; this can improve with
recellularization and long term culture.
A range of mechanical properties can be achieved based on
bio-ink selection.
Flexibility Limited availability of donor organs unless xenogeneic
tissue is used. Ability to repopulate with multiple cell
type is challenging.
Biomaterial selection and design is relatively flexible. However,
candidate materials are somewhat limited. Only 2–3
components can be printed simultaneously.
Method Maturity For certain tissue types optimized procedures have been
developed and automated for efficient decellularization
and recellularization.
Solid organs with innate vasculature has not yet been realized.
Customization Customization of size and shape is limited. Can be tailored for any size or defect.
Immunogenicity Limited immunogenicity, though studies ongoing
with respect to adaptive immune responses.
Largely unexplored, though immunological responses might be
avoided by including immunomodulatory agents in bio-ink.
Best Applications Organs with limited numbers of different cells and
high vasculature to tissue ratio (blood vessel,
lung, bladder).
Organs with intermediately complex geometries and tight packing
(bone, cartilage; more complex geometries such as heart, kidney,
liver may be possible in future).
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decellularization than with 3D bio printing. However cell
placement is more challenging with decellularized tissue,
because it is dependent on reperfusion and the subse-
quent ability of cells to attach, move and differentiate
with spatial acuity. There is evidence to support this possi-
bility, especially for organs such as the lung with 1) a high
vasculature to somatic cell ratio and 2) limited numbers of
different cell types. Thus decellularized tissues lack means
for scientists to impose spatial control of cell positioning
and the outcomes for morphogenesis depend on in situ
differentiation of delivered progenitor cells or homing cap-
abilities of differentiated cells. In contrast, 3D bio printing
accomplishes spatial acuity in a bottom-up manner
(Figs. 1b and 3b). Biop rinting technologies have been un-
ceasingly improved such that biomaterial and cells can be
placed at the time of bio printing with high resolution.
The ITOP technology is able to print at a few micrometer
scales without cells and up to 50 μm with cells. MPE-
based fabrication is capable of printing sub-micrometer
scale complexities of tissues with biomaterial. In addition,
several bio printing modalities can attain organ-level size
(Fig. 3b). The FRESH technology demonstrated nearly
identical length, width, and size of internal structures with
10 % variability, although the technology was not yet able
to print cells within the alginate scaffold. Of note, achiev-
ing micrometer-scale resolution and organ-scale size sim-
ultaneously is still challenging. At high resolution, the time
required to fabricate an organ-scale structure is limiting.
In addition, the overall tissue structure may be more crude
with 3D bio printing (especially at the current state of
technology), but the ability to incorporate not only cells
but also signaling molecules that could encourage proper
arrangement and function of incorporated cells make this
an attractive option for organs that require positioning of
multiple cell types with more limited vasculature. Since
the purpose of decellularization is to preserve the native
ECM proteins, manipulating the ECM proteins from a
decellularized organ is rarely pursued except for the use in
dECM bio-ink or self-assembling dECM for protein-
polymer hybrids. However, 3D bioprinting provides greater
flexibility in the selection of biomaterials as long as the
materials are printable and easily stabilized. This flexibility
offers the opportunity to tailor the bio-ink for appropriate
mechanical properties, microstructures, and electromech-
anical stimulation. Recent examples of bionic compos-
ites showed that electromechanical components could
be printed within a 3D bio printed organ for augmented
functionality [53] or for therapeutic control and elec-
trical stimulation to affect the engineered organs or the
host [54, 55]. In addition, patient-specified characteris-
tics of replacement tissues may become important for
successful clinical outcomes. Medical imaging can be
used to obtain precise spatial information of injured or
lost organs, and the shape and size of the targeted
organ can be reconstructed via 3D software and then
fabricated with 3D bioprinting. This customized ap-
proach bypasses the mismatch of size, shape and other
physiological conditions between donors and recipients.
Finally, a discussion of immunological outcomes of 3D
bio printed or decellularized solid organs for transplant-
ation is warranted. Decellularization chemically, physically
and enzymatically depletes immunological components
such as α-gal antigen, MHC/HLA (major histocompatibility
complex/human leukocyte antigen) and other genetic ma-
terial (Fig. 1a). Decellularized porcine livers were nonim-
munogenic for allogeneic and xenogeneic transplantation
over 28 days [56]. Decellularized human hearts after sub-
cutaneous implantation in Sprague-Dawley rats for two
weeks contained significantly more CD68+/CD163+ macro-
phages [21], suggestive of the presence of immunomodula-
tory and tissue remodeling macrophage phenotypes in the
decellualized ECM [57]. Thus decellularized ECM has been
considered immunologically inert, with exhibited construct-
ive remodeling. However, more recent studies reported that
adaptive immunity is substantially engaged in response to
implanted decellularized ECMs [58]. For example, porcine
SIS did not elicit any signs of rejection [59], but did trigger
Th2 responses [60]. In addition, human decellularized der-
mal matrix, AlloDerm®, when implanted into the abdominal
wall of adult monkeys, elicited an early and transient anti-
body response [61]. Given the data associated with immune
activation (or lack thereof) are still scattered and somewhat
contradictory, continued assessment of short and long term
immune responsiveness to decellularized tissue is needed.
3D printing technologies are less mature in assessment of
immunologic responsiveness [8, 62]. As these technologies
mature, bio-ink selection and design should consider
chronic inflammation and adaptive immunity for the
transplantation of 3D printed solid organs. Strategic de-
sign of bio-ink materials and autologous or HLA-
matched allogeneic iPSC [63] may help alleviate potential
immunological complications, but this hurdle must be
tested for clinical application of solid organs in addition
to the viability and lineage-commitment of printed stem
or progenitor cells.
Conclusions
In this review, we have highlighted important findings from
the two most promising technologies for solid organ fabri-
cation, decellularized tissue and 3D bio printing. Decellular-
ization began with great promise to regenerate cadaveric
organs while overcoming transplant rejection and possibly
alleviating perpetual shortage of donated organs. The most
recent human decellularized heart was repopulated with
RNA-induced PSCs to differentiate cardiomyocytes to avoid
the risk of genetic modification of iPSCs. Although the
recellularized cardiac slices and fibers maintained beating
phenotypes, sarcomeric structures, and electromechanical
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function, the whole heart scaffold could not exhibit the
same extent of functionality that was attained in the cardiac
slice and fibers. Thus progress at the organ level scale with
decellularized tissue is still in its infancy, but is advancing
[14]. 3D bioprinting of tissues, especially of soft tissues is
also in its infancy. 3D bioprinting can guide the placement
of cell and supporting matrix at levels corresponding to
the native tissue. Many 3D bioprinting technologies
already showed printed cells maintain good viability. The
next step is to create a solid organ with PSCs at an appro-
priate differentiation stage for transplantation. Further,
PSCs or progenitors in bio-inks need to be protected from
uncontrolled differentiation during printing and their dif-
ferentiation, proliferation, and migration should be pre-
cisely guided by spatially defined cues from matrices. In
vivo or in vitro maturation should be accompanied either
by biochemical signaling or electromechanical stimulation
[64, 65] to create a functional organ. Despite these chal-
lenges, 3D bioprinting technologies discussed here are just
beginning to achieve smaller goals for regenerative medi-
cine application including in vitro model systems and drug
testing.
4D printing technology emerges as well, conferring
printed 3D structures with the ability to change their form
or function with time under stimuli such as pressure,
temperature, wind, water or light [66, 67]. A candidate
material for 4D printing is stimuli-responsive hydrogels
mimicking the dynamics of the ECM [68], where the
hydrogel material forms a pre-defined 3D configuration.
Inspired by nastic plant motion, a calla lily flower was
printed and transformed upon swelling (Fig. 3c) [69]. This
biomimetic 4D printing technology controls the orienta-
tion of cellulose fibrils embedded in a soft acrylamide
hydrogel to define elastic and swelling anisotropies. Dur-
ing printing, the composite fibrils undergo shear-induced
alignment, leading to printed filaments with anisotropic
stiffness and swelling behavior along the filament length.
In addition, the anisotropic swelling enables precise con-
trol over curvature, which was quantified by a mathemat-
ical model for the mechanics of anisotropic objects to
manipulate the embedding of a complex surface.
In future, decellularized tissues will continue to find
their way to clinical practice as they have already for
skin and blood vessel. Generation of certain tissues not
amenable to decellularization and more importantly,
recellularization, may benefit from current or emerging
variations of 3D bio printing.
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